Seek Labs Secures $3 Million for CRISPR Cancer Research
The funding supports expanding the company's CRISPR-based Sequence Ablation Therapeutics platform into oncology.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Should foundations prioritize funding experimental medical research to address gaps in current cancer treatments?
Salt Lake City-based Seek Labs has secured up to $3 million in research funding from the Two2Ten Foundation. The capital will support the preclinical expansion of the company's Sequence Ablation Therapeutics platform into oncology research.
Why it matters
This funding accelerates the application of computational sequence analysis and CRISPR technology toward cancer treatments for populations currently underserved by standard therapies.
The Sequence Ablation Therapeutics platform leverages a combination of computational sequence analysis and programmable CRISPR technology to identify and target specific genetic sequences. The program remains in the preclinical research stage with results pending future validation in cancer models.
The players
Seek Labs
A Salt Lake City-based biotechnology firm developing computational sequence analysis and CRISPR-based therapeutic platforms.
Two2Ten Foundation
A charitable organization providing research capital to advance medical treatments, established to honor the memory of Travis Snyder.
The details
The Sequence Ablation Therapeutics platform uses a dual-process approach: computational analysis first maps target genetic sequences, which are then acted upon by programmable CRISPR technology—a tool for precise genome editing. This research phase will utilize preclinical cancer models to test the efficacy of these therapeutic candidates in inhibiting tumor growth. The process aims to provide a more targeted alternative to conventional oncology treatments.
Timeline
October 26, 2026: Seek Labs announced the research funding agreement.
The Tech Race
This development follows an industry-wide trend of applying CRISPR-based oncology therapeutics to treat underserved patient groups. The investment specifically aims to validate Seek Labs' platform against current standards in genomic intervention.
The research is currently in the preclinical stage, meaning there are no immediate clinical applications or patient treatments available. Seek Labs plans to share findings through future scientific publications and presentations as the data matures.
The takeaway
This funding provides the runway for Seek Labs to move its CRISPR-based platform into oncology research. Watch for upcoming peer-reviewed publications as the company attempts to validate its sequence ablation method in preclinical cancer models.
Further reading
Learn more about the latest developments in the Biotech sector.
Source note: This article includes information reported by Financial Post.
Live Poll
Should foundations prioritize funding experimental medical research to address gaps in current cancer treatments?
